BRIEF published on 02/17/2025 at 07:07, 1 year 6 months ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 year 6 months ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 6 months ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 6 months ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 7 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year 7 months ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 7 months ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 7 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce le traitement du premier patient dans l'essai de phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées Innate Pharma Tumeurs Solides Conjugué Anticorps-médicament IPH4502 Nectine-4
BRIEF published on 01/16/2025 at 07:05, 1 year 7 months ago Nouveau Bilan des Actions et Droits de Vote pour Innate Pharma Droits De Vote AMF Actions Ordinaires Structure Actionnariale Innate Pharma
BRIEF published on 01/16/2025 at 07:05, 1 year 7 months ago New Share and Voting Rights Report for Innate Pharma Common Shares Voting Rights AMF Shareholding Structure Innate Pharma
Published on 09/12/2026 at 02:35, 12 hours 10 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 45 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 40 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 17 hours 20 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 45 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 7 hours 15 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 30 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 35 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 19 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 30 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 19 hours ago Availability of the 2026 Interim Financial Report
